Bond A J, Curran H V, Bruce M S, O'Sullivan G, Shine P
Department of Psychiatry, Institute of Psychiatry, University of London, UK.
J Affect Disord. 1995 Dec 13;35(3):117-23. doi: 10.1016/0165-0327(95)00053-4.
23 patients with a diagnosis of panic disorder with agoraphobia were randomly assigned to 8 weeks' treatment with alprazolam or placebo. They filled in self-ratings before and after treatment and competed on a competitive reaction time task, designed to measure behavioural aggression, after 8 weeks' treatment. Patients taking both alprazolam and placebo rated decreased anxiety after 8 weeks' treatment but those on alprazolam also tended to report less hostility. On the behavioural task, patients on alprazolam behaved more aggressively in response to provocation. This is the first study to confirm clinical reports of benzodiazepine-induced dyscontrol on an objective laboratory measure. It is important that it is followed up in a larger group of patients.
23名被诊断为伴有广场恐惧症的惊恐障碍患者被随机分配接受为期8周的阿普唑仑或安慰剂治疗。他们在治疗前后填写自评量表,并在8周治疗后完成一项旨在测量行为攻击性的竞争性反应时任务。服用阿普唑仑和安慰剂的患者在8周治疗后均报告焦虑减轻,但服用阿普唑仑的患者也倾向于报告敌意减少。在行为任务中,服用阿普唑仑的患者在受到挑衅时表现得更具攻击性。这是第一项通过客观实验室测量证实苯二氮䓬类药物诱发失控的临床报告的研究。对更多患者进行随访很重要。